Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD5K3 Phase 1a study in healthy volunteers
NCT06527781Phase 1Completed
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pd5k3 in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) (3 arms), sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. Primary endpoint: Treatment-related Adverse Events up to 49 days. Started Nov 2023; status: completed.
02
Drugs
pd5k3
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT06527781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527781.